Combination of lutetium-177 labelled anti-L1CAM antibody chCE7 with the clinically relevant protein kinase inhibitor MK1775: a novel combination against human ovarian carcinoma
出版年份 2018 全文链接
标题
Combination of lutetium-177 labelled anti-L1CAM antibody chCE7 with the clinically relevant protein kinase inhibitor MK1775: a novel combination against human ovarian carcinoma
作者
关键词
-
出版物
BMC CANCER
Volume 18, Issue 1, Pages -
出版商
Springer Nature America, Inc
发表日期
2018-09-25
DOI
10.1186/s12885-018-4836-1
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Temsirolimus in women with platinum-refractory/resistant ovarian cancer or advanced/recurrent endometrial carcinoma. A phase II study of the AGO-study group (AGO-GYN8)
- (2016) Günter Emons et al. GYNECOLOGIC ONCOLOGY
- Abstract PD09-09: The Akt inhibitor MK-2206 is an effective radio-sensitizer of p53 deficient triple negative breast cancer (TNBC) cells.
- (2014) EP Connolly et al. CANCER RESEARCH
- Functional Kinomics Identifies Candidate Therapeutic Targets in Head and Neck Cancer
- (2014) R. Moser et al. CLINICAL CANCER RESEARCH
- Combined Inhibition of Wee1 and PARP1/2 for Radiosensitization in Pancreatic Cancer
- (2014) D. Karnak et al. CLINICAL CANCER RESEARCH
- Anti-L1CAM radioimmunotherapy is more effective with the radiolanthanide terbium-161 compared to lutetium-177 in an ovarian cancer model
- (2014) Jürgen Grünberg et al. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
- Paclitaxel improved anti-L1CAM lutetium-177 radioimmunotherapy in an ovarian cancer xenograft model
- (2014) Dennis Lindenblatt et al. EJNMMI Research
- New Strategies in the Treatment of Ovarian Cancer: Current Clinical Perspectives and Future Potential
- (2013) S. Banerjee et al. CLINICAL CANCER RESEARCH
- Inhibition of DNA Double-Strand Break Repair by the Dual PI3K/mTOR Inhibitor NVP-BEZ235 as a Strategy for Radiosensitization of Glioblastoma
- (2013) Carlos Rodrigo Gil del Alcazar et al. CLINICAL CANCER RESEARCH
- Monoclonal antibodies therapies for ovarian cancer
- (2013) Umberto Leone Roberti Maggiore et al. EXPERT OPINION ON BIOLOGICAL THERAPY
- Combined inhibition of Chk1 and Wee1: In vitro synergistic effect translates to tumor growth inhibition in vivo
- (2012) Laura Carrassa et al. CELL CYCLE
- Phase II study of MLN8237 (alisertib), an investigational Aurora A kinase inhibitor, in patients with platinum-resistant or -refractory epithelial ovarian, fallopian tube, or primary peritoneal carcinoma
- (2012) Ursula A. Matulonis et al. GYNECOLOGIC ONCOLOGY
- Cyclin-Dependent Kinase Suppression by WEE1 Kinase Protects the Genome through Control of Replication Initiation and Nucleotide Consumption
- (2012) H. Beck et al. MOLECULAR AND CELLULAR BIOLOGY
- WEE1 Kinase Inhibition Enhances the Radiation Response of Diffuse Intrinsic Pontine Gliomas
- (2012) V. Caretti et al. MOLECULAR CANCER THERAPEUTICS
- L1CAM
- (2012) Helena Kiefel et al. Cell Adhesion & Migration
- WEE1 inhibition sensitizes osteosarcoma to radiotherapy
- (2011) Jantine PosthumaDeBoer et al. BMC CANCER
- Recent progress in the diagnosis and treatment of ovarian cancer
- (2011) Danijela Jelovac et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Inhibiting the mTOR Pathway Synergistically Enhances Cytotoxicity in Ovarian Cancer Cells Induced by Etoposide through Upregulation of c-Jun
- (2011) H. Itamochi et al. CLINICAL CANCER RESEARCH
- WEE1 Kinase Targeting Combined with DNA-Damaging Cancer Therapy Catalyzes Mitotic Catastrophe
- (2011) P. C. De Witt Hamer et al. CLINICAL CANCER RESEARCH
- Phase II trial of the mTOR inhibitor, temsirolimus and evaluation of circulating tumor cells and tumor biomarkers in persistent and recurrent epithelial ovarian and primary peritoneal malignancies: A Gynecologic Oncology Group study
- (2011) Kian Behbakht et al. GYNECOLOGIC ONCOLOGY
- L1-CAM-targeted antibody therapy and 177Lu-radioimmunotherapy of disseminated ovarian cancer
- (2011) Eliane Fischer et al. INTERNATIONAL JOURNAL OF CANCER
- Wee1 controls genomic stability during replication by regulating the Mus81-Eme1 endonuclease
- (2011) Raquel Domínguez-Kelly et al. JOURNAL OF CELL BIOLOGY
- MK-1775, a small molecule Wee1 inhibitor, enhances anti-tumor efficacy of various DNA-damaging agents, including 5-fluorouracil
- (2010) Hiroshi Hirai et al. CANCER BIOLOGY & THERAPY
- Achievements and unmet needs in the management of advanced ovarian cancer
- (2010) Valentina Guarneri et al. GYNECOLOGIC ONCOLOGY
- The Src Inhibitor AZD0530 Blocks Invasion and May Act as a Radiosensitizer in Lung Cancer Cells
- (2010) Phillip R. Purnell et al. Journal of Thoracic Oncology
- MK-2206, an Allosteric Akt Inhibitor, Enhances Antitumor Efficacy by Standard Chemotherapeutic Agents or Molecular Targeted Drugs In vitro and In vivo
- (2010) H. Hirai et al. MOLECULAR CANCER THERAPEUTICS
- Preclinical studies and clinical utilization of monoclonal antibodies in epithelial ovarian cancer
- (2009) Peter J. Frederick et al. GYNECOLOGIC ONCOLOGY
- Phase II trial of single agent cetuximab in patients with persistent or recurrent epithelial ovarian or primary peritoneal carcinoma with the potential for dose escalation to rash
- (2009) Russell J. Schilder et al. GYNECOLOGIC ONCOLOGY
- Phase III Trial of Gemcitabine Compared With Pegylated Liposomal Doxorubicin in Progressive or Recurrent Ovarian Cancer
- (2008) Gabriella Ferrandina et al. JOURNAL OF CLINICAL ONCOLOGY
- Oregovomab Maintenance Monoimmunotherapy Does Not Improve Outcomes in Advanced Ovarian Cancer
- (2008) Jonathan Berek et al. JOURNAL OF CLINICAL ONCOLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now